Loading...
Cipla Limited — Tiotropium Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #2 for Tiotropium · $5.2M export value · DGFT Verified
Cipla Limited is the #2 Indian exporter of Tiotropium with $5.2M in export value and 104 verified shipments. Cipla Limited holds a 7.7% market share in Tiotropium exports across 16 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| MOROCCO | $1.2M | 26 | 33.7% |
| TURKEY | $550.0K | 11 | 15.8% |
| URUGUAY | $321.5K | 7 | 9.2% |
| SRI LANKA | $302.0K | 16 | 8.7% |
| URUGAY | $244.6K | 5 | 7.0% |
| COLOMBIA | $201.9K | 10 | 5.8% |
| PARAGUAY | $196.4K | 4 | 5.6% |
| MYANMAR | $148.0K | 6 | 4.3% |
| UNITED ARAB EMIRATES | $100.0K | 2 | 2.9% |
| JAMAICA | $99.7K | 3 | 2.9% |
Cipla Limited exports Tiotropium to 17 countries. The largest destination is MOROCCO accounting for 33.7% of Cipla Limited's Tiotropium shipments, followed by TURKEY (15.8%) and URUGUAY (9.2%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA MAROC | MOROCCO | $896.3K | 20 |
| SERVIMEDIC SA | URUGAY | $566.1K | 12 |
| PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR | TURKEY | $550.0K | 11 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $159.9K | 8 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UPS | COLOMBIA | $151.4K | 7 |
India exported $8.9M worth of Tiotropium through 2,210 shipments from 99 suppliers to 50 countries, serving 186 buyers globally. Cipla Limited contributes $5.2M to this total, accounting for 7.7% of India's Tiotropium exports. Cipla Limited ships Tiotropium to 17 countries through 27 buyers.
Cipla Limited's average Tiotropium shipment value is $50.0K per consignment, based on 104 shipments totaling $5.2M. The largest destination is MOROCCO (33.7% of Cipla Limited's Tiotropium exports).
Cipla Limited ranks #2 among 99 Indian Tiotropium exporters with a 7.7% market share. The top 3 exporters are CIPLA LIMITED ($5.2M), LUPIN LIMITED ($2.3M), VAMSI PHARMA PRIVATE LIMITED ($650.0K). Cipla Limited processed 104 shipments to 16 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TIOVA ROTACAPS Tiotropium Powder for Inhalation 18 mcg 16,430 PACK PACK SIZE: 15'S | $150.0K | 3 |
| TIOVA ROTACAPS (Tiotropium Powder for Inhalation 18 mcg) 15'S | $150.0K | 3 |
| TIOVA ROTACAPS (TIOTROPIUM POWDER FOR INHALATION 18 MCG) (INV.QTY.36480 PACK X15S=547200 NOS)NOS | $138.4K | 3 |
| TIOVA ROTACAPS (TIOTROPIUM POWDER FOR INHALATION 18 MCG) (INV.QTY.35570 PACK X15S=533550 NOS)NOS | $136.2K | 3 |
| TIOVA HFA INHALER TIOTROPIUM BROMIDE 9 | $127.4K | 4 |
| TIOVA HFA INHALER (TIOTROPIUM BROMIDE 9 | $122.8K | 3 |
| TIOVA ROTACAPS (TIOTROPIUM POWDER FOR INHALATION 18 MCG) (INV. QTY.25640 PACK X15S=384600 NOS)NOS | $103.5K | 3 |
| TIOVA 18MCG ROTACAPS (TIOTROPIUM BROMID | $100.0K |
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | CIPLA LIMITED ★ | $5.2M | 104 | 16 | $50.0K |
| 1 | LUPIN LIMITED | $2.3M | 45 | 2 | $50.0K |
| 3 | VAMSI PHARMA PRIVATE LIMITED | $650.0K | 13 | 3 | $50.0K |
Cipla Limited ranks #2 among 99 Indian Tiotropium exporters. Average shipment value of $50.0K compared to the market average of $90.4K. The closest competitors by value are LUPIN LIMITED and VAMSI PHARMA PRIVATE LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 705 | 31.9% |
| DELHI AIR | 424 | 19.2% |
| SAHAR AIR | 323 | 14.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 167 | 7.6% |
| Delhi Air | 131 | 5.9% |
| Bombay Air | 71 | 3.2% |
| NHAVA SHEVA SEA (INNSA1) | 36 | 1.6% |
| Bombay Air Cargo | 30 | 1.4% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Tiotropium, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Tiotropium — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Tiotropium exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
| CIPLA MAROC ANGLE RUES IBNOU TOUFAIL ET ABDELHAK |
| MOROCCO |
| $150.0K |
| 3 |
| PROSALUD FARMA S A | PARAGUAY | $146.4K | 3 |
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $142.1K | 8 |
| CIPLA MAROC ANGLE RUES IBNOU | MOROCCO | $127.7K | 3 |
| LASCO DISTRIBUTORS LTD | JAMAICA | $99.7K | 3 |
Cipla Limited supplies Tiotropium to 27 buyers globally. The largest buyer is CIPLA MAROC (MOROCCO), followed by SERVIMEDIC SA (URUGAY) and PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR (TURKEY). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| 2 |
| TIOVA 18MCG ROTACAPS TIOTROPIUM BROMIDE ROTA 18MCG 18260PACKx1X30'S=547800NUM | $100.0K | 2 |
| TIOVA ROTACAPS TIOTROPIUM POWDER FORINHALATION 18MCG 18240PACKx15'S=273600NUM | $100.0K | 2 |
Cipla Limited exports 73 distinct Tiotropium formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TIOVA ROTACAPS Tiotropium Powder for Inhalation 18 mcg 16,43 with 3 shipments worth $150.0K.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 50+ countries, 186+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Tiotropium. For current shipment-level data, contact TransData Nexus.